Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Common Equity (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Common Equity for 8 consecutive years, with -$38.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 23.35% to -$38.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$38.5 million, a 23.35% increase, with the full-year FY2025 number at -$32.2 million, changed N/A from a year prior.
  • Common Equity was -$38.5 million for Q4 2025 at Outlook Therapeutics, down from -$32.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$32.2 million in Q3 2025 to a low of -$50.3 million in Q4 2024.